Humana Dealt Another Blow: Texas Court Rejects Second Challenge to Medicare Advantage Star Ratings, Citing ‘Rational Process’ in CMS Methodology
A federal judge in Texas has dismissed Humana’s second lawsuit against the Centers for Medicare & Medicaid Services (CMS), upholding the agency’s controversial 2025 star ratings for the insurer’s Medicare Advantage (MA) plans and potentially costing the company billions in bonus payments and market share. In a ruling handed down on October 14, 2025, U.S. District Judge Reed O’Connor declared CMS’s evaluation “within the bounds of reasoned decision-making,” dealing a significant setback to Humana amid its ongoing struggles with rising medical costs and shrinking margins in the privatized Medicare program.
The focus keyword “Humana Medicare Advantage star rating lawsuit” captures the escalating stakes in this regulatory showdown, tying into CMS star ratings methodology, Medicare Advantage bonus payments, Humana financial impact 2025, federal court rulings on healthcare, and payer challenges to quality metrics that have gripped industry watchers since Humana’s initial filing in October 2024.
The Ruling: ‘Judicial Deference’ to CMS’s ‘Rational’ Approach
O’Connor’s 20-page opinion in the Northern District of Texas sided squarely with CMS and the Department of Health & Human Services (HHS), rejecting Humana’s claims that the agency acted “arbitrarily and capriciously” under the Administrative Procedure Act (APA). At the heart of the dispute: CMS penalized Humana’s customer service scores based on three “secret shopper” test calls in late 2023, which the insurer argued were flawed—one allegedly never occurred due to a technical glitch, another misattributed, and a third mishandled by a contractor. These deductions dropped a key contract from 4.5 to 3.5 stars, dragging 75% of Humana’s MA enrollment below the critical 4-star threshold for full bonuses.
“The challenged Star Ratings methodology is the product of a rational process and warrants judicial deference,” O’Connor wrote, emphasizing CMS’s discretion in quality assessments designed to guide seniors toward high-performing plans. The dismissal with prejudice bars refiling in that court, though Humana signaled it may appeal to the Fifth Circuit. A Humana spokesperson expressed “disappointment” but reaffirmed commitment to “meaningful improvements” in star performance, noting the company’s bids for 2026 already factored in a loss.
This marks Humana’s second defeat: O’Connor tossed the original suit in July 2025 for failing to exhaust administrative appeals, prompting the refiled action focused solely on the calls. CMS, silent on the ruling per policy, has defended its “mystery shopper” program as essential for unbiased evaluations, with star ratings influencing $15 billion in annual bonuses across the $450 billion MA market.
Background: A Plunge from Stars to Setbacks
Humana, the No. 2 MA provider with 5.8 million enrollees, dominated the program for years, boasting 94% of members in 4+ star plans in 2024—unlocking rebates that funded extras like dental and vision. But 2025’s scores cratered to 25% at 4 stars or higher, largely from the disputed calls affecting a contract covering 45% of its MA base and 90% of employer waivers. Analysts peg the fallout at $1-3 billion in lost 2026 revenue, exacerbating a 50% stock plunge since early 2024 amid 15% utilization spikes and flat CMS rate hikes.
The insurer joined a wave of challenges: UnitedHealth and Elevance sued last fall, with UnitedHealth securing a recalculation and Alignment Healthcare a partial win, while Florida Blue struck out. Humana’s suits echo broader gripes with CMS’s 2025 methodology tweaks, including a 2024 data lag that penalized plans for post-COVID care gaps.
Industry Reactions: ‘Expected but Painful’ Amid Mixed Legal Fortunes
Pundits called the outcome “priced in,” with Mizuho analysts noting Humana’s Q3 2025 earnings (due October 30) baked in the hit, projecting flat 2026 growth. Capstone estimated a $3 billion “windfall” evaporation, but praised Humana’s pivot to “top quartile” recovery via call center overhauls and AI-driven quality audits. On X, #MedicareStarRatings trended with broker frustration—”CMS’s black box is killing competition”—and patient advocates cheering transparency. A viral thread from @HealthPolicyPro dissected the ruling’s deference to agencies, warning of “regulatory capture” in MA’s 50% Medicare share.
Experts like Wake Forest’s David Ridley view it as a “wake-up for payers,” urging data-driven bids over litigation in a program facing Biden-era scrutiny for overpayments totaling $140 billion since 2010. HHS’s non-comment underscores its hands-off stance, but insiders hint at 2026 methodology tweaks amid congressional probes.
Impact on Seniors, Payers, & the $450B MA Market
For U.S. consumers—especially the 33 million MA enrollees eyeing open enrollment November 1—this ruling locks in Humana’s lower tiers, potentially hiking premiums or trimming perks like $0 copays in affected plans. Economically, it squeezes Humana’s $110 billion 2024 revenue (up 10% but margins at 2%), risking 2026 enrollment dips of 5-10% in competitive markets like Florida and Texas. Lifestyle ripple: Seniors in Humana-heavy states like Kentucky (its HQ) may face narrower networks or higher out-of-pocket costs, amid a 2025 CMS push for equity in rural access.
Politically, with Trump’s deregulation whispers and a divided Congress eyeing MA fraud ($60B annually), the case spotlights tensions between innovation incentives and quality safeguards. Technologically, it accelerates AI in call scoring—Humana’s piloting chatbots to hit 4.5 stars by 2027.
User intent for those searching: Enrollees check plan switchers on Medicare.gov; brokers scan 2026 bids for bonuses; investors track Humana’s appeal odds via SEC filings. Humana vows “all options,” with a potential Fifth Circuit filing by December.
As Humana Medicare Advantage star rating lawsuit, CMS star ratings methodology, Medicare Advantage bonus payments, Humana financial impact 2025, federal court rulings on healthcare, and payer challenges to quality metrics intensify, this double defeat cements CMS’s grip on MA accountability.
In summary, Judge O’Connor’s dismissal of Humana’s second star ratings challenge affirms CMS’s “rational” penalties, sealing billions in lost bonuses and pressuring the insurer’s turnaround. Looking ahead, with appeals possible and 2026 bids locked in, Humana’s fate hinges on operational fixes—while the MA market braces for a quality-over-quantity reckoning under federal watch.
By Sam Michael
Follow and subscribe to us to increase push notifications.
Humana Medicare Advantage lawsuit, CMS star ratings 2025, Medicare bonus payments impact, Humana financial setback, federal judge Reed O’Connor ruling, payer star ratings challenges, MA plan quality metrics, healthcare regulatory deference, Humana enrollment drop risk, Medicare open enrollment 2025